ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma - pravastatin sodium - film-coated tablet - 20 mg - pravastatin sodium 20 mg - pravastatin

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 80 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; iron oxide yellow; microcrystalline cellulose; croscarmellose sodium; magnesium stearate - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. pravastatin is indicated in patients: with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/l) serum cholesterol levels; with unstable angina pectoris (see actions, clinical trials). as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see actions, clinical trials).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; iron oxide yellow; brilliant blue fcf - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephritic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol / l) serum cholesterol levels. patients with unstable angina pectoris. as an adjunct to diet and lifestyle modification for the treatment of heterozygenous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; iron oxide yellow - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephritic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol / l) serum cholesterol levels. patients with unstable angina pectoris. as an adjunct to diet and lifestyle modification for the treatment of heterozygenous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

accord healthcare limited - pravastatin sodium - tablets - 10 milligram - pravastatin

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

accord healthcare limited - pravastatin sodium - tablets - 40 milligram - pravastatin

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 10 milligram(s) - hmg coa reductase inhibitors; pravastatin

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 40 milligram(s) - hmg coa reductase inhibitors; pravastatin

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 20 milligram(s) - hmg coa reductase inhibitors; pravastatin

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

viatris limited - pravastatin sodium 10mg;   - tablet - 10 mg - active: pravastatin sodium 10mg   excipient: croscarmellose sodium iron oxide yellow lactose monohydrate light magnesium oxide magnesium stearate microcelac 100 povidone - pravastatin is indicated: · in hypercholesterolemic patients without clinically evident coronary heart disease, as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. · for the reduction of elevated total and ldl-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. · as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease. · coronary artery disease: in patients with a history of either a myocardial infarction or unstable angina pectoris to reduce the risk for total mortality, chd death, recurrent coronary event (including myocardial infarction), need for myocardial revascularisation procedures, and need for hospitalisation. · cerebrovascular disease: in patients with a history of coronary artery disease (i.e. either a myocardial infarction or unstable angina pectoris) to reduce the risk of stroke or transient ischemic attacks (tias). · cardiac and renal transplantation: in patients receiving immunosuppressive therapy to improve survival in cardiac transplant patients and to reduce the risk of acute rejection in kidney transplant patients